WEN enters the week with short sellers back on the offensive — the May squeeze appears to have been a covering blip rather than a structural retreat.
The short position has rebuilt with speed. After the Trian take-private report triggered a sharp squeeze, short interest briefly pulled back but has since climbed back to 25.4% of the free float — still elevated, and up 27% over the past month in absolute share terms. Bears who covered are evidently re-establishing. What has changed is the lending market: availability has tightened to 44.6%, the lowest level in the 52-week tracked period, down from above 100% as recently as mid-April. That means fewer than one share is available to borrow for every two already lent out — the pool for new short positions is thinning fast. Cost to borrow tells a similarly charged story: it peaked at 10.6% last week and has since eased to 7.8%, still roughly seven times where it stood a month ago at 1.1%. The borrow market is materially tighter than it was before the squeeze began.
Options traders, meanwhile, are positioned for a different outcome. The put/call ratio has fallen to 0.58 — nearly two standard deviations below its 20-day average of 0.94 — and represents one of the most call-heavy readings of the past year. That is a sharp reversal from the defensive posture seen through April, when the PCR was consistently above 1.0. Taken together, the positioning setup is split: shorts are rebuilding into a thinning borrow market, while options flow leans bullish. The ORTEX short score has crept up to 76.1, its highest reading in the tracked window, ranking in the 4th percentile for short score across the universe — a signal that this remains one of the more structurally pressured names in the market.
The analyst community offered a mixed verdict in the days around the May 8 earnings print. JP Morgan downgraded to Underweight with a $6 target, making it the most bearish call from a major firm this cycle. BMO trimmed its target to $8 while staying at Market Perform. Citi nudged its target marginally higher to $7.75 but kept Neutral. Against those, Argus Research upgraded to Buy with a $12 target — the sole bullish outlier. The consensus sits at Sell, with a mean price target of $7.70, below the current price of $8.12. Bulls point to the Trian involvement, the breakfast initiative, and an EV/EBITDA of 11.5x as modest against a potential take-private premium. Bears counter that the franchise model is heavily leveraged and leaves limited room for the investment needed to compete in a tough consumer environment. The stock has risen 17% over the past month but remains deeply discounted against its own history.
Trian Fund Management's position is the elephant in the room. The activist firm holds 7.8% of shares. Nelson Peltz personally controls another 5.3%. Together, that is over 13% of the company in the hands of parties who have publicly signalled interest in a deal. Institutional flows were broadly stable into April, with BlackRock and Vanguard adding modest positions. The structural ownership story has not changed materially since the take-private reports surfaced, which is partly why short sellers are returning: the deal has not been confirmed and the stock has already rallied hard on the rumour.
The earnings reaction on May 8 — down 2.7% on the day but up 15.4% over the five days that followed — captures the tension neatly. The print was uninspiring on its own; the rally was entirely driven by the Trian story. The next confirmed earnings date is August 7. Between now and then, the story is less about Wendy's fundamentals and more about whether Peltz can secure take-private financing — and whether short sellers rebuilding into a tightening borrow market will face another squeeze before that question is answered.
See the live data behind this article on ORTEX.
Open WEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
